Molecular biology laboratories + Life science laboratories
Molecular biology laboratories + Life science laboratories
At Amaterasu, collaboration is core to our R&D philosophy. We work closely with leading academic institutions, government bodies, CROs, CMOs, and innovation incubators to accelerate breakthrough ideas and bring patient-centric technologies to market.
Malaria continues to cause millions of illnesses and hundreds of thousands of deaths each year, especially in low-resource, high-burden regions. Current Artemisinin-based therapies demand multiple oral doses over several days or monotherapy injections, leading to poor adherence, incomplete cure, and rising artemisinin resistance. Vulnerable patients often miss doses or discontinue treatment due to side effects and access barriers, resulting in relapse, complications, and ongoing transmission.
Amaterasu Lifesciences’ SiDMI is a game-changer in malaria treatment. By combining Artemether and Lumefantrine in a single-dose injection, we address the issue of non-adherence head-on. Our advanced drug delivery technology ensures effective treatment with a single administration, reducing the risk of drug resistance and improving patient outcomes.
SiDMI is a first-in-class single-dose intramuscular injection that delivers a full course of Artemisinin Combination Therapy (artemether–lumefantrine) using Amaterasu’s SMEDDS-based, in-situ gelling depot technology. After injection, the liquid rapidly transforms into a gel in the muscle, releasing both drugs in a controlled, bio-enhanced manner to achieve curative exposure from a single dose. This design directly addresses the gaps and maximises the impact of existing malaria medicines.
Patent status:
• India: Patent granted for the liquid injectable composition and depot technology.
• USA: Patent granted for the same composition and platform.
Key benefits
• Ensures 100% compliance and treatment with a single-dose injection
• Lifesaving intervention in high-risk populations – children, pregnant women
• Reduces risk of drug resistance and complications
SiDMI is designed for patients in malaria-endemic regions, particularly children and adults with limited access to continuous care. It supports public health programs, governments, and NGOs seeking scalable, field-friendly solutions with superior adherence and outcomes.
The technology platform, formulation, and preclinical pharmacokinetic/pharmacodynamic package have been established, demonstrating strong efficacy and safety in animal models. Manufacturing processes compatible with GMP scale-up have been developed, and SiDMI has already been recognised for innovation at major industry forums such as CPHI Pharma Awards.
SiDMI is being developed in collaboration with:
for bringing deep formulation and drug delivery expertise.
for its funding, validation and translational support
as its incubation partner
as development partner bringing in its manufacturing, regulatory and business development expertise.